These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 3655862)

  • 1. The effects of distance from primary treatment centers on survival among patients with multiple myeloma.
    Lenhard RE; Enterline JP; Crowley J; Ho GY
    J Clin Oncol; 1987 Oct; 5(10):1640-5. PubMed ID: 3655862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of socioeconomic and clinical factors on survival in multiple myeloma.
    Weston B; Grufferman S; MacMillan JP; Cohen HJ
    J Clin Oncol; 1987 Dec; 5(12):1977-84. PubMed ID: 3681379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma.
    Abou-Jawde RM; Baz R; Walker E; Choueiri TK; Karam MA; Reed J; Faiman B; Hussein M
    Haematologica; 2006 Oct; 91(10):1410-3. PubMed ID: 16963396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival in multiple myeloma in Kerala.
    Nair MK; Varghese C; Krishnan E; Sankaranarayanan R; Nair B
    Natl Med J India; 1993; 6(1):7-10. PubMed ID: 8453369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers: Results From the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) Program in the United States, 1990 to 2010.
    Zeng C; Wen W; Morgans AK; Pao W; Shu XO; Zheng W
    JAMA Oncol; 2015 Apr; 1(1):88-96. PubMed ID: 26182310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival.
    Abbott KC; Agodoa LY
    Clin Nephrol; 2001 Sep; 56(3):207-10. PubMed ID: 11597035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Shreveport Myeloma Experience: Survival, Risk Factors and Other Malignancies in the Age of Stem Cell Transplantation.
    Munker R; Shi R; Nair B; Devarakonda S; Cotelingam JD; McLarty J; Mills GM; Glass J
    Acta Haematol; 2016; 135(3):146-55. PubMed ID: 26588024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
    Katodritou E; Terpos E; Kastritis E; Delimpasis S; Symeonidis AS; Repousis P; Kyrtsonis MC; Vadikolia C; Michalis E; Polychronidou G; Michael M; Papadaki S; Papathanasiou M; Kokoviadou K; Kioumi A; Vlachaki E; Hadjiaggelidou C; Kouraklis A; Patsias I; Gavriatopoulou M; Kotsopoulou M; Verrou E; Gastari V; Christoulas D; Giannopoulou E; Pouli A; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
    Ann Hematol; 2015 Dec; 94(12):2033-42. PubMed ID: 26420061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of bone marrow angiogenesis in multiple myeloma: use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters.
    Bhatti SS; Kumar L; Dinda AK; Dawar R
    Am J Hematol; 2006 Sep; 81(9):649-56. PubMed ID: 16845660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
    Raje N; Faiman B; Harvey RD; Kurtin SE; Lonial S; Kumar SK; Cohen AD; Conde MA; Giralt SA; Recine MS; Tombler ER; Stadtmauer E; Jagannath S; Anderson KC;
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):356-69. PubMed ID: 25066040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.
    Long B; Chang J; Ziogas A; Tewari KS; Anton-Culver H; Bristow RE
    Am J Obstet Gynecol; 2015 Apr; 212(4):468.e1-9. PubMed ID: 25448522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of multiple myeloma in Asia: resource-stratified guidelines.
    Tan D; Chng WJ; Chou T; Nawarawong W; Hwang SY; Chim CS; Chen W; Durie BG; Lee JH
    Lancet Oncol; 2013 Nov; 14(12):e571-81. PubMed ID: 24176575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Socioeconomic status and survival in multiple myeloma].
    Pasqualetti P; Colantonio D; Collacciani A; Casale R
    Minerva Med; 1990 Oct; 81(10):713-6. PubMed ID: 2234467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma.
    Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Therneau TM; Kyle RA; Litzow MR; Gertz MA; Greipp PR
    J Clin Oncol; 1999 May; 17(5):1551-7. PubMed ID: 10334543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved survival for multiple myeloma in denmark based on autologous stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual, prognostic variables, selection bias, and clinical behavior on survival in more than 1200 patients in trials of the nordic myeloma study group.
    Johnsen HE; Klausen TW; Boegsted M; Lenhoff S; Gimsing P; Christiansen I; Gedde-Dahl T; Lindås R; Mellqvist UH;
    Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):290-6. PubMed ID: 20709667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple myeloma--diagnosis, prognostic factors and treatment].
    Kitani T
    Rinsho Ketsueki; 1995 May; 36(5):471-9. PubMed ID: 7783353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial differences in the incidence and outcomes for patients with hematological malignancies.
    Flowers CR; Glover R; Lonial S; Brawley OW
    Curr Probl Cancer; 2007; 31(3):182-201. PubMed ID: 17543947
    [No Abstract]   [Full Text] [Related]  

  • 19. Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989.
    Schaapveld M; Visser O; Siesling S; Schaar CG; Zweegman S; Vellenga E
    Eur J Cancer; 2010 Jan; 46(1):160-9. PubMed ID: 19682891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.